# Gefitinib Long-term Survivor Study

> **NCT02932345** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02932345
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-31
- **Primary completion:** 2017-07-04
- **Final completion:** 2017-07-04
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Due to strategic decision, AZ has applied to terminate study at all participating sites and has committed that the data generated during the course of the study will not be submitted to China National Medical Products Administration.
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932345, "Gefitinib Long-term Survivor Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02932345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*